Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial
- Bonnefoi, H.
- Litiere, S.
- Piccart, M.
- MacGrogan, G.
- Fumoleau, P.
- Brain, E.
- Petit, T.
- Rouanet, P.
- Jassem, J.
- Moldovan, C.
- Bodmer, A.
- Zaman, K.
- Cufer, T.
- Campone, M.
- Luporsi, E.
- Malmström, Per
- Werutsky, G.
- Bogaerts, J.
- Bergh, J.
- Cameron, D. A.
DOIAbstract
Pathological complete response (pCR) following chemotherapy is strongly associated with both breast cancer subtype and long-term survival. Within a phase III neoadjuvant chemotherapy trial, we sought to determine whether the prognostic implications of pCR, TP53 status and treatment arm (taxane versus non-taxane) differed between intrinsic subtypes. Patients were randomized to receive either six cycles of anthracycline-based chemotherapy or three cycles of docetaxel then three cycles of eprirubicin/docetaxel (T-ET). pCR was defined as no evidence of residual invasive cancer (or very few scattered tumour cells) in primary tumour and lymph nodes. We used a simplified intrinsic subtypes classification, as suggested by the 2011 St Gallen consens...
Add to ORKG